Audit: QRS - Colloidal Silver for Health & Longevity
Audit conducted on 12/09/2026 08:23 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 85 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every variable region. At-a-glance tracks ER Conclusion (lines 470–472); protocol cells track ER Therapeutic Protocol bullets (lines 342–346, 354); time cells track ER Practical Considerations “Time to effect” (line 401) and ER line 350; gates track ER lines 291–318; benefits/risks track ER headings; monitoring table and qualitative list track ER lines 425–444. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “No measured effect to time” and “No human benefit endpoint has been met, so no onset can be stated” (lines 514, 518) mirror ER lines 350 and 401. Marker 8 target keeps the ER’s “No established numeric target” wording (line 736). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications stay absolute and remain in the STOP gate; at-a-glance “Oral use has no demonstrated benefit in people” matches ER “What has not been shown is that oral use produces any measured benefit in people” (line 470). |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | All 8 stop items come from the ER’s “Populations who should avoid Colloidal Silver” list (lines 311–318); all 9 caution items come from the ER’s interaction bullets (lines 291–307). No Benefit- or Risk-Modifying Factor content appears in any gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS contains no PMIDs, citations, author names, NCT identifiers or brand names anywhere. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Objective, exposure-accounting framing throughout, matching the ER’s own register. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Presents thresholds, doses and markers as decision inputs rather than warnings; the reader is left able to act on the data. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | No imperatives; protocol cells describe what labels direct and what routes deliver. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Cadence and monitoring entries are stated descriptively (“Baseline, then serum silver and photographs at three months…”, line 752). |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No recommending or advising verbs appear in the document’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained are the precise ones required by the ER (argyria, eGFR, Child-Pugh); at-a-glance uses fully plain wording. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate items and tier items are reduced to key facts; every ER rationale, severity grade and mitigation clause is stripped. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-text scan for “you”/”your”; no matches. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content assumes willingness to run trace-element assays, standardised photography and six-monthly panels. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | 24-hour urine collection, metal-free tubes implied by serum silver, and photographic tracking are retained rather than simplified away. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Functional targets (ALT/AST below 25 U/L, eGFR above 90, selenium 110–150 µg/L) are tighter than conventional ranges, as expected for this audience. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The sheet foregrounds the cumulative-exposure trade-off and the topical-versus-oral distinction, which is the decision this audience faces. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not appear; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Routes are named formally: “Maintenance oral dosing”, “Short-course oral dosing”, “Topical and mucosal application”, “retained sublingually” (lines 450, 464, 478, 457). No “taken by mouth”, “pill” or “shot” anywhere. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All headings match the template byte-for-byte (lines 446, 492, 541, 599, 628, 761, 560, 575, 632–634); tier labels “Medium: “, “Low: “, “Speculative: “ are unmodified. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 38 template spans are present; the generic marker_#_* and qualitative_item_# spans are expanded to marker_1..8_* and qualitative_item_1..5 as intended. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | <span website="evidence_review">, <span website="audit"> and <span website="full_review"> are byte-identical to the template (lines 423, 426, 440); the entire style block, footer and disclaimer are unchanged. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section is empty; the unpopulated benefit/risk tiers are governed by items 12.5 and 13.5, not by an empty-state phrasing. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels “Maintenance oral dosing”, “Short-course oral dosing”, “Topical and mucosal application” are the ER’s bold labels verbatim (ER lines 342–346); caution items reuse the ER’s bold interaction labels (ER lines 291–307). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Marker names match the ER biomarker table verbatim (“Serum silver”, “24-hour urine silver”, “ALT and AST”, “Creatinine and eGFR”, “CBC with differential”, “Serum selenium”, “TSH”, “Standardised skin and gum photographs”). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Full-text scan finds no emoji; the ER’s “⚠️ Conflicted” markers are correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed rather than transcribed: multi-sentence ER risk entries collapse to single clauses, and interaction bullets lose their severity/consequence/mitigation text. No second-page structure or overflow markup was introduced. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14: the metadata comment opens on line 2, immediately after <!doctype html> on line 1, and precedes the template comment on line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3, closing --- on line 13; the title text on line 2 precedes the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | The block sits entirely inside <!-- ... --> and no metadata value is repeated in the header, subline or footer. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly, because it contains a colon; all other values are bare and untrimmed of nothing. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: colloidal_silver_2026-0912-0416_Opus_ER.md, matching the ER’s own filename frontmatter value. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.9.11, matching the version badge at the head of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0912-0755, in the required YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version number with no context-window or other qualifier appended. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: colloidal_silver_2026-0912-0416_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys including git_user: evipedia-1 and git_issue: 6078; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: Colloidal Silver for Health & Longevity - Quick Reference Sheet, matching ER canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: Colloidal Silver for Health & Longevity, with no suffix and the ampersand encoded. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 09/12/2026, the correct MM/DD/YYYY rendering of qrs_creation_date: 2026-0912-0755. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: Opus 5, identical to the qrs_creator_ai_fullname frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header block (lines 415–428) carries only the title and the template subline; the ER’s alternate_names list is not reproduced. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Lines 434–438 compress both Conclusion paragraphs (ER lines 470–472) and close on the actionable topical-versus-oral distinction. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | Counted at exactly 60 words, within the limit. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | “Silver does kill microbes on contact” (ER 470), dressings as the source of healing evidence (ER 470), no improvement over saltwater (ER 470), accumulation in skin/eyes/liver/kidney and permanent discoloration (ER 472), topical keeps exposure local (ER 472). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “saltwater”, “blue-grey discoloration” and “builds up” are lay-register throughout. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | Refers to “the one controlled human comparison” without naming the trial, author or year. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No odds ratio, confidence interval or standardized mean difference appears; the ER’s OR 4.02 figure is not carried over. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All items trace to the “Populations who should avoid Colloidal Silver” list inside that ER section (ER lines 309–318). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All 8 ER avoidance populations are present, in ER order, with none added or omitted (lines 563–570). |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Each of the 8 entries is a standalone <li> inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER rationale clause is stripped: “in whom silver crosses the placenta…”, “whose lower body weight…”, “in whom biliary elimination is impaired”, “given the one documented neurological case”. No dash-trailing clause survives. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | The eGFR threshold “(eGFR below 45 mL/min/1.73 m²)” and the staging “Child-Pugh Class B or C” are retained (lines 565–566); only the ER’s definitional gloss of eGFR is trimmed. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses anywhere in Key Interactions & Contraindications. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names eight such populations, and the section is correspondingly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty, so no absence comment is required. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All 9 items map one-to-one onto the ER’s interaction bullets at ER lines 291–307. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | No overlap with the 8 stop items; all 9 ER interaction bullets are represented (lines 578–589). |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Each of the 9 entries is a standalone <li> inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every mechanism, severity grade, consequence and mitigation sentence is stripped; the ER’s “Other interventions — “ dash prefix is removed from the implants/water item (line 589). |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All four ER example-drug lists survive: tetracyclines, fluoroquinolones, the antacid/PPI/H2 list and the thiol-donor list (lines 578–587); only the redundant “all stomach-acid reducers:” gloss is trimmed. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s parentheses contain only plain comma-separated drug names, with no ranking symbols. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names nine interactions, and the section is correspondingly populated rather than empty. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty, so no absence comment is required. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from ER Therapeutic Protocol bullets at ER lines 342, 344, 346, with the dosing-window detail from ER line 354. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The ER’s three executable regimens — maintenance oral, short-course oral, topical/mucosal — are selected ahead of the non-actionable bullets (competing approaches, origin, half-life, genetics). |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three or more actionable aspects, so no set is unused. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans carry ER-derived content: “5 mL of 10 ppm once daily”, “Up to 7 teaspoons daily, 7–10 days”, “10–30 ppm, 2–3× daily”, each with a supporting sub-line (lines 450–488). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Topical, systemic and accumulation are exactly the three aspects the ER’s “Time to effect” bullet distinguishes (ER line 401). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Topical — the only tier with a rated benefit (Low) — is first; systemic, where no benefit endpoint has been met, follows; accumulation, which carries no benefit, is last. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects, so no set is unused. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans are populated: “Immediate”, “No measured effect to time”, “Within 14 days”, each with an ER-derived sub-line (lines 498–533). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Both populated tiers map onto ER Expected Benefits headings (ER lines 161, 169–183). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans are present at lines 543–553 with the correct tier assignment. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Reduced to bare headings; the ER’s OR 4.02 magnitude, confidence intervals, funding caveat and mechanistic text are all dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in either benefit item; the ER’s “⚠️ Conflicted” marker on antibacterial activity is also removed. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | benefits_high and benefits_medium are emptied and set to style="display: none" (lines 543–544), correctly reflecting ER lines 153 and 157. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All three populated tiers map onto ER headings at ER lines 209, 217–249 and 255–273. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans are present at lines 601–622 with the correct tier assignment. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each ER heading collapses to a single clause; the ER’s Magnitude paragraphs, case details and EPA reference-dose figures are all omitted. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses in any risk item; the ER’s glosses (“continuous seizure-driven muscle jerking”, “a cancer of blood-forming cells”) and “⚠️ Conflicted” markers are stripped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | risks_high is emptied and set to style="display: none" (line 601), correctly reflecting ER line 205. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | The table reproduces the ER Monitoring Protocol & Defining Success biomarker table (ER lines 427–436), including its “Why Measure It?” column text. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 8 ER biomarkers are present in ER order: serum silver, 24-hour urine silver, ALT and AST, creatinine and eGFR, CBC with differential, serum selenium, TSH, standardised photographs. Every target value matches the ER verbatim. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 751–755 carry the full cadence, matching the ER’s baseline, three-month, six-month and six-to-twelve-month schedule (ER line 425). |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All five entries come from the ER’s “Qualitative markers worth tracking alongside the laboratory values” list (ER lines 440–444). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All 5 ER qualitative markers are present verbatim and in ER order (lines 764–789). |
Issues 12/09/2026 08:23
Pass rate 100.00%. No issues found.
Issues 12/09/2026 08:16
- 2.8 — Protocol sub-cells restate their values: action_1_sub (line 457) opens with “One teaspoon”, which repeats “5 mL” already in action_1_value (line 453), and action_2_sub (line 471) opens with “Roughly 350 micrograms daily for no more than seven to ten days”, repeating both the amount and the window already in action_2_value “Up to 7 teaspoons daily, 7–10 days” (line 467).
Fixes 12/09/2026 08:16
- 2.8 — Protocol sub-cells restate their values: Trimmed action_1_sub from “One teaspoon, about 50 micrograms of silver, retained sublingually before swallowing” to “About 50 micrograms of silver, retained sublingually before swallowing”, removing the duplicate of “5 mL” in action_1_value. Trimmed action_2_sub from “Roughly 350 micrograms daily for no more than seven to ten days” to “Roughly 350 micrograms of silver daily”, removing the duplicate of the “7 teaspoons daily, 7–10 days” already in action_2_value.
Issues 12/09/2026 08:07
- 1.3 — Argyria hedge dropped in lede: The
at_a_glancespan (QRS line 436) states that “permanent blue-grey discoloration follows months of daily use”, strengthening the ER Conclusion’s “permanent blue-grey discoloration is well documented after months of daily use” (ER line 472) from an evidentiary observation into a deterministic consequence.
Fixes 12/09/2026 08:07
- 1.3 — Argyria hedge restored in lede: Changed
at_a_glancefrom “permanent blue-grey discoloration follows months of daily use” to “permanent blue-grey discoloration is well documented after months of daily use”, matching the ER Conclusion. The preceding “and” was replaced with a semicolon to keep the span at 60 words, within the 7.2 limit.
Issues 12/09/2026 08:02
- 2.8 — Time-to-effect sub restates value: [time_2_sub] at lines 517–519 (“Systemically there is no measured effect to time.”) is a verbatim restatement of [time_2_value] at line 514 (“No measured effect to time”) and carries no additional information, unlike the parallel subs for time_1 and time_3.
Fixes 12/09/2026 08:02
- 2.8 — Redundant time-to-effect sub: Replaced [time_2_sub] “Systemically there is no measured effect to time.” with “No human benefit endpoint has been met, so no onset can be stated.”, so the sub adds ER-supported information (ER line 350) instead of restating [time_2_value].